Rockwell Medical to Buy Vantive's Global Hemodialysis Business for $125M in Seller Financing
RMTI sits 66% above its 52-week low of $4.885 on elevated volume (2.4× avg).
Summary
Rockwell Medical agreed to acquire Vantive's global hemodialysis business for a $125M base price, funded entirely by $100M of seller term loans and a $25M convertible note, with up to $45M of earnouts. The combined company is projected at $400M-$450M in annual revenue, but Rockwell withdrew its 2026 guidance and closing is not expected until mid-2027.
Key Events · M&A and Partnerships · RMTI
-
Acquisition of Vantive Hemodialysis Business
Rockwell will acquire Vantive's in-center hemodialysis business across 35 jurisdictions — concentrates, AK-98 machines, water treatment systems, bloodlines and technical services — plus the one-million-square-foot Medolla, Italy manufacturing campus, for a $125,000,000 base purchase price.
-
Seller-Financed Consideration, No Cash Outlay
The closing consideration is paid entirely by Vantive affiliates: $100,000,000 in two $50,000,000 term loan tranches plus a $25,000,000 convertible note. Term loans bear Term SOFR (2.50% floor) plus 5.50% and 7.00% respectively, rising 0.75% per year, maturing in six years.
-
Convertible Note Conversion at $14.94
The $25,000,000 note converts at $14.94 per share, 200% of a $7.47 reference price, and pays 3.0% PIK interest. Conversion is capped at 19.99% of shares outstanding until stockholders approve excess issuance under Nasdaq Rule 5635.
-
Up to $45M Contingent Earnout
Vantive can receive up to $45,000,000: 30% of pro forma EBITDA above $10,000,000 (capped at $25,000,000) plus two $10,000,000 payments if pro forma revenue exceeds $480,000,000 and $500,000,000 within the first five fiscal years.
Analysis · RMTI · Life Sciences
Rockwell, a roughly $33M-market-cap concentrates maker with about $17.8M in quarterly sales, is acquiring a business projected to generate $400M-$450M in annual revenue — several times its own size. The deal is paid for entirely with paper from the seller: $100M of term loans plus a $25M convertible note, so no cash leaves Rockwell at closing, but the company takes on substantial secured debt with interest stepping up annually and a conversion price of $14.94 that could add meaningful dilution later. Rockwell also withdrew its 2026 guidance for sales, gross margin, Adjusted EBITDA and operating cash flow because of transaction and financing costs, removing the near-term earnings anchor. Closing is targeted for mid-2027 and hinges on regulatory and foreign investment clearances, including Italian golden power, plus Vantive's separation from Baxter's IT systems — a long list of conditions between announcement and completion.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 50.3% of the 199 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RMTI was trading at $8.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.6M. The 52-week trading range was $4.89 to $12.90. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.